A Study of QLS2404 Injection in Healthy Participants and Participants With Rheumatic Autoimmune Diseases

NCT07751315 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus
Primary Sjögren's Syndrome

Interventions

DRUG: Ia:QLS2404 very low dose
DRUG: Ia:QLS2404 low dose
DRUG: Ia:QLS2404 middle dose
DRUG: Ia:QLS2404 high dose
DRUG: Ia:QLS2404 Max dose
DRUG: Ib:QLS2404 low dose
DRUG: Ib:QLS2404 middle dose
DRUG: Ib:QLS2404 high dose

Sponsor

Qilu Pharmaceutical Co., Ltd.